ArticleJournal of substance use and addiction treatment2026
Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.
Article in Journal of substance use and addiction treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionLong-acting injectable buprenorphine may be a promising treatment option for adolescents and young adults with opioid use disorder (OUD). However, little is known about its safety, tolerability, and effectiveness in this age group.
methodsWe conducted a 1-year feasibility study of elective inpatient buprenorphine induction followed by administration of long-acting injectable buprenorphine and linkage to ongoing substance use care in individuals <21 years in a safety-net health system (n = 18).
resultsEighteen of 22 (82%) of patients admitted to an inpatient unit for buprenorphine initiation opted to receive the long-acting injectable formulation upon completion of induction. Of 18 patients who received long-acting injectable buprenorphine, 15 (83%) and 12 (67%) remained in care at one- and two-months post discharge, respectively. Eleven (61%) participants received repeat doses at both one- and two-months post discharge. Fourteen (78%) and 12 (67%) participants had not returned to opioid use at one- and two- months post discharge, respectively.
conclusionThe findings from this study of adolescents and young adults with OUD demonstrated that inpatient initiation of long-acting injectable buprenorphine after a brief induction with short-acting buprenorphine may be safe, well tolerated, and effective in terms of linkage, retention in care, and return to opioid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.